VACcination of LIver Transplantation Candidates

Launched by HOSPICES CIVILS DE LYON · Jun 22, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how effective vaccinations are for people waiting for a liver transplant. Since patients with liver disease often have weakened immune systems, they are more vulnerable to serious infections. The researchers want to find out if the current vaccination schedule recommended for liver transplant candidates provides enough protection against infections six months after the transplant. They aim to better understand how well these vaccines work in this specific group of patients.

To participate in the trial, individuals must be at least 18 years old and waiting for a liver transplant. They should have been referred for evaluation by a liver disease specialist and must agree to take part in the study. However, certain individuals, such as those who have received specific treatments or have certain health conditions, may not be eligible. Participants will receive vaccinations and will be monitored to assess the effectiveness and safety of these vaccines. This research is important because it could help improve vaccination strategies for liver transplant candidates, ultimately leading to better health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age ≥ 18 years old
• • patients waiting for liver transplantation referred by hepato-gastroenterology department as part of the pre-transplant evaluation to the infectiology consultation
• • patient who were informed of the study and did not object to participate
• Exclusion Criteria:
• • patient candidate for multi-organ transplant
• • patient who received immunosuppressive therapy, biotherapy and/ or corticosteroid therapy at a dose greater than 10 mg / day of prednisone equivalent for more than 2 weeks within 3 months before vaccination (6 months of rituximab)
• • patient who received polyvalent immunoglobulins within the 6 months before the serological evaluation
• • patient who received systemic anti-cancer chemotherapy for solid tumor or hemopathy within 6 months preceding the start of vaccination
• • splenectomized patients
• • asplenic patients for a reason other than liver disease
• • chronic infection with the human immunodeficiency virus (HIV)
• • patient with any other hereditary immune deficiency or acquired which could compromise the vaccine response or interpretation of serological results
• • patient under legal protection measure or unable to consent to the study